<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964623</url>
  </required_header>
  <id_info>
    <org_study_id>VVR_2019_5</org_study_id>
    <nct_id>NCT03964623</nct_id>
  </id_info>
  <brief_title>Impact of Nicotine on Retinal Vascularization</brief_title>
  <acronym>TABARET</acronym>
  <official_title>Impact of Nicotine on Retinal Vascularization (Tabaret)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main hypothesis is the nicotine is associated with a modification of retinal
      micro-vascularization.

      Patients will be recruited during their ophthalmologic consultation at the Rothschild
      Foundation, an OCT-A will be realized and data relating to medical history, oral
      contraceptive intake and nicotine consumption via cigarette or e-cigarette data will be
      collected.

      The objective is to seek an association between retinal vascular density and inhaled nicotine
      intake.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Density of retinal vascular Plexus (quantitative variable expressed as a percentage) using OCT-A.</measure>
    <time_frame>At the inclusion consultation</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tabagism</condition>
  <arm_group>
    <arm_group_label>smokers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>vapers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non smokers/non vapers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OCT-A (Optical Coherence Tomography)</intervention_name>
    <description>Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception</description>
    <arm_group_label>non smokers/non vapers</arm_group_label>
    <arm_group_label>smokers</arm_group_label>
    <arm_group_label>vapers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People presenting to an ophthalmologic consultation at the Foundation Rothschild will be
        included in one of the 3 groups: smokers, non-smokers/non-vapers or vapers if they meet the
        inclusion and non-inclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  For group of smokers: Patient reporting active smoking for at least 3 months and at
             least 1 cigarette per day on average over a week

          -  For group of vapers : Patient using exclusively the electronic cigarette with a
             nicotine level of more than 6mg/ml for at least 3 months and at least 1 times per day
             on average over a week.

          -  For group of no-smokers no-vapersNon-smoking and no vaping, for more than 6 months

        Non-inclusion criteria:

          -  Caffeine intake within 2 hours prior to the OCT-A exam

          -  ametropia greater than + 3 dioptres of hyperopia or-3 dioptres of myopia

          -  astigmatism greater than 2 dioptres

          -  Known retinal or retina vascular pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vivien Vasseur</last_name>
    <phone>+33148036437</phone>
    <email>vvasseur@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Am√©lie Yavchitz</last_name>
    <phone>+33148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivien VASSEUR</last_name>
      <phone>148036440</phone>
      <phone_ext>+33</phone_ext>
      <email>vvasseur@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCT-A</keyword>
  <keyword>smokers</keyword>
  <keyword>vapers</keyword>
  <keyword>non-smokers/non-vapers</keyword>
  <keyword>nicotine</keyword>
  <keyword>retinal micro-vascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

